Drug Trial Radar · NCT03316560
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
Last checked: Nov 20, 2026Latest source record: May 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
29
Actual
Start
Apr 16, 2018
Primary completion
Nov 9, 2023
Study completion Mar 2025
Sponsor
- Lead sponsor
- Beacon TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 6 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.
Conditions
- X-Linked Retinitis Pigmentosa
Interventions
rAAV2tYF-GRK1-RPGRBiological
Adeno-associated virus vector expressing a human RPGR gene
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and proportion of Adverse EventsTime frame: Day 0 - Month 36
- Number and proportion of participants experiencing abnormal clinically relevant hematology or clinical chemistry parameters.Time frame: Day 0 - Month 36
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Duke University
Durham, North Carolina
Cincinnati Eye Institute
Cincinnati, Ohio
Casey Eye Institute
Portland, Oregon
Retina Foundation of the Southwest
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.